237 related articles for article (PubMed ID: 15728921)
1. Novel acyclic nucleoside phosphonate analogues with potent anti-hepatitis B virus activities.
Ying C; Holy A; Hocková D; Havlas Z; De Clercq E; Neyts J
Antimicrob Agents Chemother; 2005 Mar; 49(3):1177-80. PubMed ID: 15728921
[TBL] [Abstract][Full Text] [Related]
2. 6-[2-phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines: a new class of acyclic pyrimidine nucleoside phosphonates with antiviral activity.
Balzarini J; Pannecouque C; Naesens L; Andrei G; Snoeck R; De Clercq E; Hocková D; Holý A
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1321-7. PubMed ID: 15571252
[TBL] [Abstract][Full Text] [Related]
3. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro.
Delaney WE; Yang H; Miller MD; Gibbs CS; Xiong S
Antimicrob Agents Chemother; 2004 Oct; 48(10):3702-10. PubMed ID: 15388423
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
5. Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge.
De Clercq E
Biochem Pharmacol; 2007 Apr; 73(7):911-22. PubMed ID: 17045247
[TBL] [Abstract][Full Text] [Related]
6. Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2'-deoxyribose, on wild-type and mutant hepatitis B virus replication.
Kumar R; Semaine W; Johar M; Tyrrell DL; Agrawal B
J Med Chem; 2006 Jun; 49(12):3693-700. PubMed ID: 16759112
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of novel bis(L-amino acid) ester prodrugs of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) with improved anti-HBV activity.
Fu X; Jiang S; Li C; Xin J; Yang Y; Ji R
Bioorg Med Chem Lett; 2007 Jan; 17(2):465-70. PubMed ID: 17074481
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
Brunelle MN; Lucifora J; Neyts J; Villet S; Holy A; Trepo C; Zoulim F
Antimicrob Agents Chemother; 2007 Jun; 51(6):2240-3. PubMed ID: 17371827
[TBL] [Abstract][Full Text] [Related]
9. Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
Luo M; Groaz E; Andrei G; Snoeck R; Kalkeri R; Ptak RG; Hartman T; Buckheit RW; Schols D; De Jonghe S; Herdewijn P
J Med Chem; 2017 Jul; 60(14):6220-6238. PubMed ID: 28682067
[TBL] [Abstract][Full Text] [Related]
10. Pronounced in vitro and in vivo antiretroviral activity of 5-substituted 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy] pyrimidines.
Balzarini J; Schols D; Van Laethem K; De Clercq E; Hocková D; Masojidkova M; Holý A
J Antimicrob Chemother; 2007 Jan; 59(1):80-6. PubMed ID: 17124193
[TBL] [Abstract][Full Text] [Related]
11. Does pre-treatment with lamivudine prime for adefovir resistance of hepatitis B virus infection?
Sirma H; Funk A; Gerlich W; Schildgen O
J Antimicrob Chemother; 2007 Aug; 60(2):448-9. PubMed ID: 17561492
[No Abstract] [Full Text] [Related]
12. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
[TBL] [Abstract][Full Text] [Related]
13. [Design, synthesis and anti-HBV activity of L-amino acid ester prodrugs of acyclic nucleoside phosphonates].
Fu XZ; Jiang SH; Yang YS; Ji RY
Yao Xue Xue Bao; 2008 May; 43(5):495-503. PubMed ID: 18717337
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture.
Heijtink RA; Kruining J; de Wilde GA; Balzarini J; de Clercq E; Schalm SW
Antimicrob Agents Chemother; 1994 Sep; 38(9):2180-2. PubMed ID: 7811041
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B virus resistance to adefovir in a nucleotide naive patient with chronic hepatitis B virus infection.
Laoi BN; Herra C; Norris S; Crowley B
J Antimicrob Chemother; 2007 Apr; 59(4):807-9. PubMed ID: 17332006
[No Abstract] [Full Text] [Related]
16. Inhibition of hepatitis B virus (HBV) replication by pyrimidines bearing an acyclic moiety: effect on wild-type and mutant HBV.
Semaine W; Johar M; Tyrrell DL; Kumar R; Agrawal B
J Med Chem; 2006 Mar; 49(6):2049-54. PubMed ID: 16539393
[TBL] [Abstract][Full Text] [Related]
17. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
Cha CK; Kwon HC; Cheong JY; Cho SW; Hong SP; Kim SO; Yoo WD
J Med Virol; 2009 Mar; 81(3):417-24. PubMed ID: 19152409
[TBL] [Abstract][Full Text] [Related]
18. Adefovir for lamivudine resistant HBV: more than meets the eye.
Di Marco V; Craxì A
J Hepatol; 2007 Oct; 47(4):618-9; author reply 619-20. PubMed ID: 17697727
[No Abstract] [Full Text] [Related]
19. Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression.
Leemans WF; Janssen HL; Niesters HG; de Man RA
J Viral Hepat; 2008 Feb; 15(2):108-14. PubMed ID: 18184193
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.
Qi X; Xiong S; Yang H; Miller M; Delaney WE
Antivir Ther; 2007; 12(3):355-62. PubMed ID: 17591025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
